Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financing will support Phase 2 clinical trials in psoriasis and ulcerative colitis.

The post Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics appeared first on MedCity News.

“Botched math” in calculating clinical data for an autoimmune disease drug is one of the allegations Nektar Therapeutics makes in a legal complaint against Eli Lilly. The biotech claims its former partner tried to disadvantage the asset in order to advance development of another drug it acquired in a billion dollar deal.

The post Nektar Sues Eli Lilly, Claiming the Big Pharma Breached Contract to Favor Another Drug appeared first on MedCity News.

Dice Therapeutics reported the first human data for its oral psoriasis drug designed to hit the same pro-inflammatory protein blocked by blockbuster antibody drugs from Novartis and Eli Lilly. The potential for Dice’s pill to offer a competitive oral alternative pushed the biotech’s stock skyward by nearly 80%.

The post A biologic’s efficacy in a pill: Dice posts first human data for oral psoriasis med appeared first on MedCity News.

Plaque psoriasis drug Vtama is now approved by the FDA, making it the first novel topical treatment for the chronic autoimmune disorder in a generation. Roivant Sciences subsidiary Dermavant Sciences acquired the drug from GlaxoSmithKline in 2018.

The post FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years appeared first on MedCity News.

The FDA cited manufacturing issues in turning down UCB’s application seeking approval for bimekizumab, an antibody drug developed to treat moderate-to-severe plaque psoriasis. Bimekizumab is already approved and available in other markets around world, but the FDA rejection delays UCB’s antibody drug from competing in the U.S. for now.

The post UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug appeared first on MedCity News.

The company which recently raised $18 million, has a connected device that is approved for Medicare coverage of psoriasis, while its smartphone app offers opportunities for engaging patients beyond treatment.

The post With smartphone-connected home light therapy, Clarify Medical breaks new ground in psoriasis appeared first on MedCity News.

Bristol-Myers Squibb said Celgene would sell the drug, Otezla (apremilast), to Amgen. The pharmaceutical company had said it would seek a divestment of the drug to satisfy competition concerns from the FTC.

The post Celgene to sell psoriasis drug to Amgen for $13.4B, clearing key hurdle to BMS deal appeared first on MedCity News.

The drugmaker said Monday it would sell off the drug Otezla to address concerns about competition that the Federal Trade Commission had expressed in connection to the pending $74 billion deal. According to an analyst, BMS saw Otezla as competitive against its investigational TYK2 inhibitor.

The post BMS to sell $1.6B psoriasis drug to satisfy FTC concerns about Celgene acquisition appeared first on MedCity News.

Coming soon to a screen near you: more psoriasis ads. FDA has approved J&J’s guselkumab (Tremfya) for use in moderate to severe plaque psoriasis. Despite plenty of competition, annual sales are expected to be north of $1 billion by 2022.

The post More options for psoriasis, as Big Pharma jostles for market share appeared first on MedCity News.

Purdue Pharma has announced a strategic partnership with Exicure, which could be worth up to $790 million and royalties if the latter’s drug candidates succeed. The first disease target, psoriasis, is well outside of Purdue’s painkiller market — probably not by accident.

The post Purdue and Exicure sign deal worth up to $790M appeared first on MedCity News.

LEO Pharma, which has had a primary focus on skin conditions like psoriasis, has launched its new Innovation Lab to further explore treatment options that don’t involve medication.

The post LEO Pharma launches new innovation lab with $65M in funding for non-pharmaceutical dermatology expansion appeared first on MedCity News.

The post Morning Read: AstraZeneca deal for psoriasis drug valued at up to $445M appeared first on MedCity News.

The post Should patients see a psychologist to help manage conditions like acne or psoriasis? appeared first on MedCity News.

The post Skylit’s handheld device could bring psoriasis, eczema phototherapy home appeared first on MedCity News.

The post AbGenomics developing monoclonal antibody-based psoriasis treatment, raises $13.6M appeared first on MedCity News.

The post Biotech accelerator BioMotiv, NYU unveil a new spinoff for inflammatory disease treatments appeared first on MedCity News.